Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

This article was originally published in PharmAsia News

Executive Summary

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

You may also be interested in...



As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China

The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.

As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China

The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.

As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In Rising China

BEIJING - German pharmaceutical powerhouse Bayer Schering is engineering an alliance with Chinese scientists to create a global research and development center in Beijing, according to senior Bayer executives

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC069171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel